Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Elise A. Olsen, Eric C. Vonderheid, Nicola Pimpinelli et al. · Blood · 2007 · 1.4K citations

Medicine, Dermatology, Oncology +10

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

B.H. Thiers · Yearbook of Dermatology and Dermatologic Surgery · 2008 · 978 citations

Medicine, Dermatology, Oncology +10

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · Journal of Clinical Oncology · 2010 · 845 citations

Medicine, Dermatology, Oncology +17